Data regarding cancer risk management for mutations in moderate- and low-risk genes, such as RAD51C and RAD51D, are limited compared with those in high-risk genes, such as BRC one and BRCA2. However, these genes still pose an increased risk of certain cancers, with the absolute risk estimated at 20% and 10%–20% for BC and ovarian cancer, respectively (Table 1) (8). This evidence concerns the gene BRCA2 and breast cancer.